



January 27, 2015

Company Name	3 - D M a t r i x , L t d .
A d d r e s s	3-2-4, Kojimachi, Chiyoda, Tokyo
P r e s i d e n t	Kentaro Takamura
Code Number	7777
C o n t a c t	Director Tomoyuki Arai
T E L	+81 3 (3511)3440

**3-D Matrix Ltd.'s Subsidiary Signs New Exclusive Patent License Agreements  
with Massachusetts Institutes of Technology (MIT)**

The 3-D Matrix group is working towards commercialization of medical products based on the self-assembling peptide technology. The company would like to announce that 3-D Matrix Ltd.'s subsidiary in Singapore, 3-D Matrix Asia Pte. Ltd., has signed world-wide exclusive patent license agreements with MIT regarding incorporation and usage of modified self-assembling peptides and peptide surfactant technology.

The license on incorporation and usage of modified self-assembling peptides enables addition of short motif to existing peptide chain, activating biological functions. Currently, modified self-assembling peptide technology is mainly used in the regenerative medicine area. The addition of this license broadens the company's rights on cell growth enhancing peptides in the area such as bone tissues, skin tissues, myocardial tissues, and nerve tissues.

Furthermore, the peptide surfactant technology has been used in the drug delivery system field as carriers of drugs or treatment materials. The new license grants rights to additional peptide sequence. In combination with the ultra short peptide technology license concluded with Exploit Technology Pte Ltd, a technology transfer arm for the Agency of Science, Technology and Research in Singapore May 2014, the company now has a wider range of peptide sequences to develop new carriers for sustained release of molecules.

The addition of new exclusive licenses described above expands the company's rights on various self-assembling peptide sequences and intellectual properties portfolio. As such, the 3-D Matrix group will continue to develop beneficial medical products and increase corporate value.

These licenses granted do not influence the earning forecast of the company at this moment.